BIIB - Biogen/ Eisai Alzheimer's therapy Leqembi approved in Japan
2023-09-25 06:55:38 ET
More on Biogen, Eisai, etc.
- Eisai: Lumpy Rollout Of Leqembi, Economic Value Hard To Ascertain (Rating Downgrade)
- Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play
- Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects
- Eisai: Looking To Upside Targets Following Leqembi Full Approval
- Reata shareholders clear buyout deal with Biogen
For further details see:
Biogen/ Eisai Alzheimer’s therapy Leqembi approved in Japan